TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of July 6, 2026, TGTX trades at $54.94 with a market cap of $8.16B and a P/E ratio of 16.56. TGTX moved +3.04% today. Year to date, TGTX is +79.19%; over the trailing twelve months it is +46.90%. Its 52-week range spans $25.28 to $57.38. Analyst consensus is buy with an average price target of $52.67. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TG Therapeutics Starts Phase 2 Trial of BRIUMVI in 60 Treatment-Resistant Schizophrenia Patients: TG Therapeutics has launched an open-label Phase 2 trial evaluating BRIUMVI in approximately 60 adults with schizophrenia unresponsive to standard antipsychotics. The study’s primary endpoint is the proportion of participants achieving at least a 20% reduction in PANSS total score at Week 12.
| Metric | Value |
|---|---|
| Price | $54.94 |
| Market Cap | $8.16B |
| P/E Ratio | 16.56 |
| EPS | $3.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $57.38 |
| 52-Week Low | $25.28 |
| Volume | 640.96K |
| Avg Volume | 0 |
| Revenue (TTM) | $700.35M |
| Net Income | $461.90M |
| Gross Margin | 83.05% |
7 analysts cover TGTX: 0 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $52.67.